Risks of oral anticoagulant therapy with increasing age.

BACKGROUND Oral anticoagulation in the elderly is a dilemma. Although many elderly patients have strict indications for treatment with coumarin derivatives, the tendency toward an increased bleeding risk with age is a matter of concern. We investigated the risk of hemorrhage and thromboembolism according to age in patients who were treated with oral anticoagulants in the routine setting of an anticoagulation clinic. METHODS All patients of the Leiden Anticoagulation Clinic (Leiden, the Netherlands) who were treated because of mechanical heart valve prostheses (target, international normalized ratio [INR] of 3.5), atrial fibrillation (target, INR of 3.0), or after a myocardial infarction (target, INR of 3.0) between 1994 and 1998 were included in the study and grouped by age at the start of follow-up. We calculated incidence rates of major hemorrhage and thromboembolism per age group. RESULTS We included 4202 patients: 842 patients younger than 60 years; 1200 patients aged between 60 and 70 years; 1464 patients aged between 71 and 80 years; and 696 patients older than 80 years. The incidence rate of major hemorrhage rose gradually with age from 1.5 per 100 patient-years for patients younger than 60 years to 4.2 per 100 patient-years for patients older than 80 years, yielding a hazard ratio of 2.7 (95% confidence interval, 1.7-4.4). The incidence rate of major thromboembolism rose from 1.0 per 100 patient-years for patients younger than 60 years to 2.4 per 100 patient-years for patients older than 80 years (hazard ratio, 2.2; 95% confidence interval, 1.2-4.2). CONCLUSIONS The incidence of both bleeding and thromboembolic events increases sharply with advanced age. Because higher thromboembolic risk with age often makes it unfeasible to withhold oral anticoagulation from elderly patients, future studies should focus on ways to lower the bleeding risk.

[1]  R. Hultcrantz,et al.  Acquired platelet dysfunction may be an aetiologic factor in Heyde's syndrome – normalization of bleeding time after aortic valve replacement , 2002, Journal of internal medicine.

[2]  D. Grobbee,et al.  Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial , 2002, The Lancet.

[3]  V. Fuster,et al.  ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conference , 2001, Circulation.

[4]  J. Hirsh,et al.  Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study. , 2000, Archives of internal medicine.

[5]  M. Prins,et al.  Safety of Treatment with Oral Anticoagulants in the Elderly , 1999, Drugs & aging.

[6]  R. Gibbons,et al.  ACC/AHA Guidelines for the Management of Patients With Valvular Heart Disease. Executive Summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Valvular Heart Disease). , 1998, The Journal of heart valve disease.

[7]  R. Gibbons,et al.  ACC/AHA Guidelines for the Management of Patients With Valvular Heart Disease. Executive Summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Valvular Heart Disease). , 1998, The Journal of heart valve disease.

[8]  M. Moia,et al.  Thrombotic Events during Oral Anticoagulant Treatment: Results of the Inception-cohort, Prospective, Collaborative ISCOAT Study , 1997, Thrombosis and Haemostasis.

[9]  J. Garcìa,et al.  Pathogenesis of leukoaraiosis: a review. , 1997, Stroke.

[10]  J. Vandenbroucke,et al.  Assessment of a Bleeding Risk Index in Two Cohorts of Patients Treated with Oral Anticoagulants , 1996, Thrombosis and Haemostasis.

[11]  S. Fihn,et al.  The Risk for and Severity of Bleeding Complications in Elderly Patients Treated with Warfarin , 1996, Annals of Internal Medicine.

[12]  J. Vandenbroucke,et al.  Optimal oral anticoagulant therapy in patients with mechanical heart valves. , 1995, The New England journal of medicine.

[13]  F A Mathewson,et al.  The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. , 1995, The American journal of medicine.

[14]  G. Albers,et al.  Atrial fibrillation and stroke. Three new studies, three remaining questions. , 1994, Archives of internal medicine.

[15]  F. R. Rosendaal,et al.  Thromboembolic and Bleeding Complications in Patients With Mechanical Heart Valve Prostheses , 1994, Circulation.

[16]  J. Vandenbroucke,et al.  Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. , 1993, Archives of internal medicine.

[17]  J. Heikkilä,et al.  Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. , 1993, Journal of the American College of Cardiology.

[18]  F R Rosendaal,et al.  A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy , 1993, Thrombosis and Haemostasis.

[19]  Leandro Provinciali,et al.  Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke , 1993 .

[20]  L Goldman,et al.  Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. , 1989, The American journal of medicine.

[21]  Palle Petersen,et al.  PLACEBO-CONTROLLED, RANDOMISED TRIAL OF WARFARIN AND ASPIRIN FOR PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL FIBRILLATION The Copenhagen AFASAK Study , 1989, The Lancet.